Bronstein, Gewirtz & Grossman, LLC Is Investigating Neogen Corporation (NEOG) And Encourages Investors to Connect

By ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / October 13, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neogen Corporation ("Neogen" or "the Company") (NASDAQ:NEOG). Investors who purchased Neogen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/neogen-corporation-neog-class_action_lawsuit.

Neogen Investigation Details

On September 29, 2026, the U.S. Food and Drug Administration ("FDA") announced that it had issued a warning letter to Neogen "following an investigation that linked a veterinary wound care product labeled as sterile, Neogen Vet HYCOAT (hyaluronate sodium sterile solution), to serious infections and deaths in horses." The FDA said that "[t]his incident involved at least 20 horse deaths, making it the largest number of horse deaths ever associated with a quality defect in an FDA-regulated veterinary medical product and the most deaths of any animal species linked to microbiological contamination of an FDA-regulated product labeled as sterile" and further stated that "Neogen initiated a voluntary recall of HYCOAT in late January 2026." Following this news, Neogen's stock price fell $0.99 per share, or 7.22%, to close at $12.73 per share on September 29, 2026.

What's Next for Neogen Investors?

If you are aware of any facts relating to this investigation or purchased Neogen securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/neogen-corporation-neog-class_action_lawsuit. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Neogen Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Neogen Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View the original press release on ACCESS Newswire

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.